SCHEMBL6778792

SCHEMBL6778792

CS(=O)(=O)Oc1ccc2c(c1)CC1CC2CN(Cc2ccccc2)C1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.45
DRD2 P14416 5/20 0.39
DRD3 P35462 3/20 0.39
CHRNB2 P17787 2/20 0.38
CHRNA4 P43681 2/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA7 P36544 1/20 0.38
STS P08842 1/20 0.38
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PTPN1 P18031 1/20 0.37
S1PR5 Q9H228 1/20 0.37
LMNA P02545 2/20 0.36
MAPK1 P28482 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5996688 0.88 DRD2 (0.46) DRD2DRD3CHRNB2CHRNA4CHRNA7
Hydrochloric Acid SCHEMBL7860155 0.87 DRD2 (0.46) DRD2DRD3STSS1PR5CA12
SCHEMBL5997736 0.86 CHRNB2 (0.52) DRD2DRD3CHRNB2CHRNA4CHRNB4
Hydrochloric Acid SCHEMBL5995210 0.85 CHRNB2 (0.51) DRD2DRD3CHRNB2CHRNA4CHRNB4
SCHEMBL5997232 0.84 CHRNB2 (0.56) FAAHDRD2DRD3CHRNB2CHRNA4
Hydrochloric Acid SCHEMBL6814278 0.83 CHRNB2 (0.55) FAAHDRD2DRD3CHRNB2CHRNA4
SCHEMBL5996730 0.81 CHRNB2 (0.55) DRD2DRD3CHRNB2CHRNA4CHRNB4
SCHEMBL6777528 0.79 SLC6A2 (0.43) DRD2DRD3MAPTKDM4ES1PR5
Hydrochloric Acid SCHEMBL6773315 0.78 SLC6A2 (0.43) DRD2DRD3MAPTKDM4ES1PR5
SCHEMBL5996694 0.78 CHRNB2 (0.49) DRD2DRD3CHRNB2CHRNA4CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6706702-B2 FOR THERAPY OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS PFIZER INC. 2004-03-16 US disclosed
US-20030008890-A1 Aryl fused azapolycyclic compounds COE JOTHAM WADSWORTH (US) 2003-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008890-A1 Aryl fused azapolycyclic compounds GRIN2C, GRIN2A, NR3C1 FAAH 1220/4885DRD2 75/4885DRD3 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.